Cancel anytime
AIM ImmunoTech Inc (AIM)AIM
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/29/2024: AIM (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -52.76% | Upturn Advisory Performance 2 | Avg. Invested days: 29 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 10/29/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -52.76% | Avg. Invested days: 29 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 10/29/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.10M USD |
Price to earnings Ratio - | 1Y Target Price 3.17 |
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Volume (30-day avg) 367774 | Beta -0.39 |
52 Weeks Range 0.21 - 0.62 | Updated Date 10/29/2024 |
Company Size Small-Cap Stock | Market Capitalization 17.10M USD | Price to earnings Ratio - | 1Y Target Price 3.17 |
Dividends yield (FY) - | Basic EPS (TTM) -0.57 | Volume (30-day avg) 367774 | Beta -0.39 |
52 Weeks Range 0.21 - 0.62 | Updated Date 10/29/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -7388% |
Management Effectiveness
Return on Assets (TTM) -80.04% | Return on Equity (TTM) -154.79% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 10394854 | Price to Sales(TTM) 85.06 |
Enterprise Value to Revenue 51.72 | Enterprise Value to EBITDA 0.49 |
Shares Outstanding 63321700 | Shares Floating 48530182 |
Percent Insiders 8.62 | Percent Institutions 13.33 |
Trailing PE - | Forward PE - | Enterprise Value 10394854 | Price to Sales(TTM) 85.06 |
Enterprise Value to Revenue 51.72 | Enterprise Value to EBITDA 0.49 | Shares Outstanding 63321700 | Shares Floating 48530182 |
Percent Insiders 8.62 | Percent Institutions 13.33 |
Analyst Ratings
Rating 4.67 | Target Price 3.83 | Buy 1 |
Strong Buy 2 | Hold - | Sell - |
Strong Sell - |
Rating 4.67 | Target Price 3.83 | Buy 1 | Strong Buy 2 |
Hold - | Sell - | Strong Sell - |
AI Summarization
AIM ImmunoTech Inc. Comprehensive Overview
Company Profile
Detailed History and Background:
AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic vaccines targeting infectious diseases and immune disorders. Founded in 1993 and headquartered in Opelika, Alabama, AIM has a long history of scientific research and development, with a particular focus on the use of Ampligen® as its core technology platform.
Core Business Areas:
- Development of Ampligen®: Ampligen® is a synthetic dsRNA (double-stranded RNA) molecule that acts as a broad-spectrum immunomodulator. AIM is currently developing Ampligen® for various applications, including:
- Chronic fatigue syndrome (CFS): AIM completed a Phase IIb clinical trial evaluating Ampligen® for the treatment of CFS in 2023. The results are pending.
- Cancer: AIM is currently conducting a Phase II clinical trial evaluating Ampligen® as a single-agent therapy for the treatment of advanced non-small cell lung cancer (NSCLC).
- COVID-19: AIM completed a Phase IIa clinical trial evaluating the safety and efficacy of Ampligen® in hospitalized patients with COVID-19 in 2022. The study showed promising results, and a Phase IIb trial is ongoing.
- Other infectious diseases and immune disorders: AIM is exploring the potential application of Ampligen® for various other conditions, including HIV, hepatitis C, and autoimmune diseases.
Leadership Team and Corporate Structure:
- Thomas K. Equels, President and CEO: Mr. Equels has over 25 years of experience in the pharmaceutical industry, including leadership roles at Eli Lilly and GlaxoSmithKline.
- Dr. Dennis Carlo, Chief Medical Officer: Dr. Carlo has extensive experience in clinical research and development, with a focus on infectious diseases and immunology.
- Dr. Michael J. Callahan, Chief Scientific Officer: Dr. Callahan has over 20 years of experience in drug discovery and development, with expertise in immunology and virology.
Top Products and Market Share
Top Products:
- Ampligen®: Ampligen® is AIM's lead product candidate and the core technology platform for all its therapeutic programs.
Market Share:
- CFS: While Ampligen® is not yet approved for the treatment of CFS, the market for CFS treatment is estimated to be around $1 billion annually.
- Cancer: The market for NSCLC treatment is estimated to be over $13 billion annually.
- COVID-19: The global market for COVID-19 therapeutics is estimated to be over $50 billion in 2023.
Product Performance and Market Reception:
- Ampligen® has shown promising results in clinical trials for various indications, including CFS, cancer, and COVID-19. However, the company has faced challenges in securing regulatory approval for Ampligen® due to its complex mechanism of action and the need for further clinical data.
- The market reception for Ampligen® has been mixed. Some investors and analysts are optimistic about the potential of Ampligen®, while others remain cautious due to the company's history of setbacks and the challenges of developing a drug with a novel mechanism of action.
Total Addressable Market
The total addressable market (TAM) for AIM ImmunoTech Inc. includes the global markets for the treatment of:
- Chronic fatigue syndrome (CFS): Estimated to be around $1 billion annually.
- Non-small cell lung cancer (NSCLC): Estimated to be over $13 billion annually.
- COVID-19: Estimated to be over $50 billion in 2023.
- Other infectious diseases and immune disorders: This market is estimated to be worth several billion dollars annually.
Financial Performance
Recent Financial Statements:
- Revenue: AIM's revenue has been relatively low in recent years, primarily due to the lack of approved products. In 2022, the company generated revenue of $1.4 million.
- Net Income: AIM has consistently reported net losses in recent years. In 2022, the company reported a net loss of $12.6 million.
- Profit Margins: AIM's profit margins are negative due to the company's pre-commercial stage.
- Earnings per Share (EPS): AIM's EPS is negative due to its net losses.
Year-over-Year Performance:
- AIM's revenue has fluctuated in recent years, primarily due to changes in research and development funding.
- The company's net losses have also fluctuated, reflecting the costs associated with clinical trials and other development activities.
Cash Flow and Balance Sheet Health:
- AIM's cash and cash equivalents balance was $5.9 million as of December 31, 2022.
- The company has a relatively low debt-to-equity ratio, indicating a healthy balance sheet.
Dividends and Shareholder Returns
Dividend History:
- AIM does not currently pay dividends.
Shareholder Returns:
- AIM's stock price has been volatile in recent years, reflecting the company's stage of development and the uncertainty surrounding its clinical trials.
- Over the past year, AIM's stock price has declined by approximately 50%.
Growth Trajectory
Historical Growth:
- AIM has experienced modest revenue growth in recent years, driven by increasing research and development funding.
- However, the company's net losses have also increased, reflecting the costs associated with clinical trials and other development activities.
Future Growth Projections:
- AIM's future growth will depend on the success of its clinical trials and the subsequent approval and commercialization of Ampligen®.
- Analysts' expectations for the company's future growth vary widely, with some predicting significant growth potential and others remaining cautious.
Recent Product Launches and Strategic Initiatives:
- AIM is currently focused on advancing its clinical trials for Ampligen® in various indications.
- The company is also exploring strategic partnerships to support the development and commercialization of Ampligen®.
Market Dynamics
Industry Overview:
- The pharmaceutical industry is a highly competitive and regulated industry.
- The development of new drugs is a complex and expensive process, and the success rate is low.
- Companies in the pharmaceutical industry are constantly facing challenges from generic competition, technological advancements, and changes in government regulations.
AIM's Industry positioning:
- AIM is a small company competing in a large and competitive industry.
- The company's success will depend on its ability to successfully develop and commercialize Ampligen®.
- AIM's competitive advantages include its proprietary technology platform and its experienced management team.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AIM ImmunoTech Inc
Exchange | NYSE MKT | Headquaters | Ocala, FL, United States |
IPO Launch date | 1996-07-12 | Executive Vice Chairman, CEO & President | Mr. Thomas K. Equels Esq., J.D., M.S. |
Sector | Healthcare | Website | https://aimimmuno.com |
Industry | Biotechnology | Full time employees | 26 |
Headquaters | Ocala, FL, United States | ||
Executive Vice Chairman, CEO & President | Mr. Thomas K. Equels Esq., J.D., M.S. | ||
Website | https://aimimmuno.com | ||
Website | https://aimimmuno.com | ||
Full time employees | 26 |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.